Navigation Links
EGEN, Inc. Announces the Promotion of Jason Fewell, Ph.D., to Vice-President of Preclinical Research and Development
Date:8/7/2009

HUNTSVILLE, Ala., Aug. 7 /PRNewswire/ -- EGEN, Inc. (EGEN), a biopharmaceutical company specializing in nucleic acid therapeutics and delivery, announced today that Jason Fewell, Ph.D., has been promoted from Director of Biology and Pharmacology to Vice-President of Preclinical Research and Development.

Dr. Fewell possesses more than 10 years management and scientific leadership experience in the biotechnology industry and has served at EGEN since 2003 as Director of Biology and Pharmacology. During his tenure at EGEN he has helped lead the development and testing of proprietary discovery and development initiatives contributing to a strong intellectual property position. He has been instrumental in building EGEN's research and development team and has helped foster important industry collaborations. Dr. Fewell received his Ph.D. in Biological Science from Florida State University and was a post-doctoral fellow at Cincinnati's Children Hospital. During his active career in research and development, Dr. Fewell has authored numerous scientific publications and is a named inventor on several patents and patent applications in the area of non-viral gene and siRNA delivery.

About EGEN, Inc.

EGEN, Inc., is a privately held biopharmaceutical company located in Huntsville, Alabama and is focused on developing therapeutics for the treatment of human diseases via nucleic acid (DNA and RNAi) delivery. The Company has a significant intellectual property position in delivery systems, their novel compositions with nucleic acids and their therapeutic applications. EGEN's research pipeline includes products involving siRNA, shRNA and plasmid DNA for the treatment of various cancers and other diseases and has a number of collaborations with outside investigators, biotech organizations and universities on various projects in these areas.

For more information on EGEN, please visit http://www.egeninc.com/ .


'/>"/>
SOURCE EGEN, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. EGEN, Inc. Announces the Promotion of Khursheed Anwer, Ph.D., to President and Chief Scientific Officer
2. AOBO Announces New Product Launch
3. Prix Galien USA Announces 2009 Final Candidates
4. Onyx Pharmaceuticals Announces Pricing of Concurrent Offerings of Four Million Shares of Common Stock and $200 Million Principal Amount of Convertible Senior Notes
5. ThermoGenesis Announces Expanded Collaboration With Celling Technologies
6. Novavax Announces Appointment of Frederick W. Driscoll as Vice President, Chief Financial Officer and Treasurer
7. Telik Announces Second Quarter 2009 Financial Results
8. deCODE genetics Announces Webcast of Conference Call to Discuss Second Quarter 2009 Financial Results
9. Webcast Alert: Transgenomic Inc. Announces Second Quarter 2009 Earnings Release Conference Call Webcast
10. PharmatrophiX, Initially Funded by the Alzheimers Drug Discovery Foundation, Announces Exclusive Global Collaboration with Elan
11. Oncothyreon announces webcast of second quarter 2009 financial results conference call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2017)... ... 2017 , ... The first human cell line HeLa, established in 1951, has ... cross-contamination of human cell lines with HeLa cells were published. Until recently, cross-contamination and ... and is associated with dramatic consequences for research. , In this educational webinar, ...
(Date:6/22/2017)... MA (PRWEB) , ... June 22, 2017 , ... Charm ... ILVO validation. The AMPH test was determined to be appropriate as a screening test ... visual interpretation, on the Charm EZ system, and the Charm EZ Lite system. These ...
(Date:6/20/2017)... Florida (PRWEB) , ... June 20, 2017 , ... Biologist ... in men. While researching her latest book, Men Chase, Women Choose: The Neuroscience of ... that love has a physiological effect on men. ”The logical next step, in my ...
(Date:6/20/2017)... June 20, 2017  Kibow Biotech Inc., a pioneer ... the issuance of a new patent covering a unique ... the U.S. Patent and Trademark Office on May 23 ... the Buzz of Bio award in 2014 in ... developing non-drug approaches to chronic disease. Renadyl™, the first ...
Breaking Biology Technology:
(Date:4/5/2017)... 5, 2017 Today HYPR Corp. , ... server component of the HYPR platform is officially ... end-to-end security architecture that empowers biometric authentication across Fortune ... already secured over 15 million users across the financial ... connected home product suites and physical access represent a ...
(Date:3/30/2017)... 30, 2017  On April 6-7, 2017, Sequencing.com will ... hackathon at Microsoft,s headquarters in ... focus on developing health and wellness apps that provide ... the Genome is the first hackathon for personal ... largest companies in the genomics, tech and health industries ...
(Date:3/28/2017)... -- The report "Video Surveillance Market by ... Devices), Software (Video Analytics, VMS), and Service (VSaaS, Installation ... 2022", published by MarketsandMarkets, the market was valued at ... reach USD 75.64 Billion by 2022, at a CAGR ... considered for the study is 2016 and the forecast ...
Breaking Biology News(10 mins):